Page 63 - MemoriaBBN-Eng

www.ciber-bbn.es

GBIO group has developed during the last few years an outstanding expertise in

the design and fabrication of Micro-Nano-Bio devices based either on silicon or
biocompatible polymers. Biological signals obtained with these devices are usually

subjected to post-acquisition conditioning and processing with the help of totally

integrated systems.

• A, A ; B, e ; C, e ; A, P ; G, B (G, B)[ 2,3 ] ; B, J ;
Most relevant ltunAellistriidivArAlAleAtrizerGAnzo
GABriel, G ; GuimerA, A ; villA, r; Fernández, lJ; de lA PridA, lm. SU-8 based micropro-
scientific bes for simultaneous neural depth recording and drug delivery in the brainLAB CHIP.

articles
2013;13(7):1422-1430.
• P-A e, A l, C-P n, G-r J, B e. Iridium oxide pH
rAtslFonsoBAdAsAñAstoronzAlouizAldriCh
sensor for biomedical applications. Case urea-urease in real urine samples.Biosens
Bioelectron. 2013 Jan 15;39(1):163-9.
á
• AltunA A, Bellistri e, Cid e, AivAr P, GAl B, BerGAnzo J, GABriel G, Guimerà A, villA r, Fer- ñ
lJ, m P l. SU-8 based microprobes for simultaneous neural depth
nndez enendezde lA ridA
recording and drug delivery in the brain.Lab on a chip. 2013;13(7): 1422-1430.
à
• v Jl, v m, B B, J m, s A, P F .. miRNA let-7e modulates the
iAsentAyolrüneunGolAiet Al
Wnt pathway and early nephrogenic markers in mouse embryonic stem cell differen-
tiation.PLoS One. 2013;8(4):e60937.

• Guimer A, illA X, trAver e, PlAtA-Cordero m, yeste J, herrero C et Al.. Flexible probe for in

vivo quantification of corneal epithelium permeability through non-invasive tetrapolar
impedance measurements.Biomed Microdevices. 2013 Oct;15(5):849-58.

AT MOLECULAR LEVEL:
Highlights
• Advances in simulation, design and manufacture of microelectrodes to measure car-
diac and ophthalmologic biomarkers.

• Processes for the use of Graphene as a neural interface are optimized. (project re-

quested at H2020 FET-Flagships).
AT TISSUE LEVEL:

• Two clinical trials to validate a Microsystem allowing quantifying corneal permeability

in a non-invasive way have been launched.
AT ORGAN LEVEL:

• The group reported that miRNA let-7-e causes the differentiation of embryonic stem

cells to renal lineage through modulation of GSK 3 Beta and production of beta catenin.
(The work has been awarded with the “Ten best abstracts” award in the “50 th Inter-

national Congress of the European Renal Association, Dialysis and Transplantation”).
• The team with the Hospital Vall d’Hebron has patented a method that predicts the

evolution of lupus nephritis, based on the quantification of gene expression level in
urine neurofilina1 gene.

• A Microsystem with Microfluidics has been developed to simulate structures hepatic

(liver on chip) as well as for monitoring in vitro blood-brain barrier (BBB on chip).
13
SYSTEM-LEVEL:
20
T
• Seven pilot observational multicentric studies in collaboration with two other universi- OR
P
ties and four hospitals have been launched to measure the stress level and to develop RE
ad-hoc electronic instrumentation.
L
A
• As a result of a project in collaboration with CIBERES, a device for oxygen therapy is NU
N
under development with the company BVentura SL.
A
• A “zero power” device for monitoring the abdominal pressure is under development N /
B
whilst a “ultra-low-power” technology is used for other parameters. The group is also -B
working in “energy harvesting” devices to validate their inclusion in biomedical sys- R
BE
tems.
CI

The Group has launched four new patents, defended a PhD thesis and initiated seven 63
other PhD lines.